Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 566

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Open access
Suter, Thomas M., Procter, Marion, van Veldhuisen, Dirk J., Muscholl, Michael, Bergh, Jonas, Carlomagno, Chiara, Perren, Timothy, Passalacqua, Rodolfo, Bighin, Claudia, Klijn, Jan G.M., Ageev, Fail T., Hitre, Erika, Groetz, Juergen, Iwata, Hiroji, Knap, Malgorzata, Gnant, Michael, Muehlbauer, Susanne, Spence, Alison, Gelber, Richard D., Piccart-Gebhart, Martine J.·2007·Journal of Clinical Oncology
DOI 10.1200/jco.2006.09.1611
Open this paper in CoChat — free account

Abstract

Purpose: The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy. Patients and Methods: The Herceptin Adjuvant (HERA) trial is a three-group, multicenter, open-label randomized trial that compared 1 or 2 years of trastuzumab given once every 3 weeks with observation in patients with HER-2–positive breast cancer. Only patients who after completion of (neo)adjuvant chemotherapy with or without radiotherapy had normal left ventricular ejection fraction (LVEF ≥ 55%) were eligible. A repeat LVEF assessment was performed in case of cardiac dysfunction. Results: Data were available for 1,693 patients randomly assigned to 1 year trastuzumab and 1,693 patients randomly assigned to observation. The incidence of trastuzumab discontinuation due to cardiac disorders was low (4.3%). The incidence of cardiac end points was higher in the trastuzumab group compared with observation (severe congestive heart failure [CHF], 0.60% v 0.00%; symptomatic CHF, 2.15% v 0.12%; confirmed significant LVEF drops, 3.04% v 0.53%). Most patients with cardiac dysfunction recovered in fewer than 6 months. Patients with trastuzumab-associated cardiac dysfunction were treated with higher cumulative doses of doxorubicin (287 mg/m 2 v 257 mg/m 2) or epirubicin (480 mg/m 2 v 422 mg/m 2) and had a lower screening LVEF and a higher body mass index. Conclusion: Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.09.1611

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 566

Metadata

Authors
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., Ageev, F. T., Hitre, E., Groetz, J., Iwata, H., Knap, M., Gnant, M., Muehlbauer, S., Spence, A., Gelber, R. D., & Piccart-Gebhart, M. J.
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2007-09-01
Volume
25
Issue
25
Pages
3859-3865
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2006.09.1611
OpenAlex
W2101253730
Cited by
566
References
14
FWCI
27.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. https://app.cochat.ai/papers/10.1200/jco.2006.09.1611
The paper
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., Ageev, F. T., Hitre, E., Groetz, J., Iwata, H., Knap, M., Gnant, M., Muehlbauer, S., Spence, A., Gelber, R. D., & Piccart-Gebhart, M. J. (2007). Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.09.1611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.